Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 163Terminated 66Recruiting 42Active not recruiting 41Unknown 36Withdrawn 10Not yet recruiting 9Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 6Stomach Neoplasms 5Melanoma 5Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Glioblastoma 4Breast Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Myelodysplastic Syndromes 3Glioma 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Sarcoma 2Rectal Neoplasms 2Peritoneal Neoplasms 2Osteosarcoma 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Mesothelioma, Malignant 2Lymphoma 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Diffuse Intrinsic Pontine Glioma 2Warts 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thrombocythemia, Essential 1

Interventions

olaparib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Suspended × Urinary Bladder Neoplasms × Clear all
NCT03375307 2026-06-05

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

National Cancer Institute (NCI)

Phase 2 Suspended
60 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡